Pancare announces further funding to improve the treatment of pancreatic cancer using new treatments
Pancreatic cancer has one of the highest death rates of all cancers, with only about 7% of patients surviving to 5 years after diagnosis. The most effective current chemotherapy treatments of pancreatic cancer can be quite toxic and the average increase in life expectancy is only a few months. Better treatments are urgently required.
There has been great interest in therapies that target the genetic changes within the cancer. The PAK family of enzymes appears to be over-activated in most pancreatic cancers and is important in cancer growth and spread. Drug therapies that target PAK may significantly improve patient treatment and survival.
Work in this area previously funded by Pancare and undertaken by Professor Baldwin has led to a new research study across Austin Health and the University of Melbourne. This research represents an interdisciplinary collaboration led by a pancreatic surgeon-scientist, Mr Mehrdad Nikfarjam and cell biologists with unrivaled expertise in animal models of pancreatic cancer, PAK biology, tumor microenvironment and stromal activation.
Donations can be made to the Pancare Foundation here.
You can join our mailing list to hear more about the work of the Pancare Foundation fighting pancreatic cancer here.